Erlangen

Running trials

• Recruiting

  A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

  NCT07647328· Phase 3· Source

• Recruiting

  A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  NCT07391657· Phase 3· Source

• Recruiting

  A Study of AZD0120 in Autoimmune Diseases

  NCT07295847· Phase 1/2· Source

• Recruiting

  AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

  NCT06137144· Phase 1/2· Source

• Recruiting

  A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

  NCT06129864· Phase 3· Source

• Active, not recruiting

  Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

  NCT06109779· Phase 3· Source

• Active, not recruiting

  A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice.

  NCT05637112· Source

• Active, not recruiting

  Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

  NCT04784715· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers1 recruiting
• Head and neck cancer1 recruiting
• Hodgkin lymphoma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Rheumatoid arthritis1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Researchers

No researcher is linked here yet.